RFG Advisory’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $208K | Buy |
+2,507
| New | +$208K | ﹤0.01% | 885 |
|
|
2024
Q3 | – | Sell |
-2,337
| Closed | -$217K | – | 780 |
|
|
2024
Q2 | $217K | Buy |
2,337
+24
| +1% | +$2.23K | 0.01% | 662 |
|
|
2024
Q1 | $219K | Buy |
+2,313
| New | +$219K | 0.01% | 672 |
|
|
2023
Q4 | – | Sell |
-2,958
| Closed | -$216K | – | 687 |
|
|
2023
Q3 | $216K | Buy |
+2,958
| New | +$216K | 0.01% | 586 |
|
|
2023
Q1 | – | Sell |
-2,552
| Closed | -$231K | – | 662 |
|
|
2022
Q4 | $231K | Buy |
+2,552
| New | +$231K | 0.01% | 564 |
|
|
2022
Q3 | – | Sell |
-2,689
| Closed | -$248K | – | 643 |
|
|
2022
Q2 | $248K | Buy |
2,689
+123
| +5% | +$11.3K | 0.01% | 494 |
|
|
2022
Q1 | $231K | Buy |
2,566
+6
| +0.2% | +$540 | 0.01% | 462 |
|
|
2021
Q4 | $287K | Buy |
+2,560
| New | +$287K | 0.02% | 403 |
|
|
2020
Q3 | – | Sell |
-1,827
| Closed | -$204K | – | 426 |
|
|
2020
Q2 | $204K | Buy |
+1,827
| New | +$204K | 0.03% | 366 |
|